Search
Powered By HealthLine
Special Offers
Health Tools
 Heart Healthy Diet
 Ideal Body Weight Calculator
 Diet Reviews
 Fitness and Family
 Quiz: Test Your Fitness IQ
 Exercise and Fitness Guide
 Eat Out Smart
 Healthy Cooking
 BMI Calculator
Featured Conditions
 Diet & Exercise
 Stop Smoking
 Food & Fitness
 High Blood Pressure
 Cholesterol
 Heart
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today



Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

Blood-Thinner No Help for Dialysis Treatment

Plavix didn't improve results for patients who underwent circulatory procedure

By Ed Edelson
HealthDay Reporter


Related Encyclopedia
 border=
Aneurysms
Angina Pectoris
Angiogram
Angiography
More...

Related Healthscout Videos
 border=
Importance of Good Nutrition
Controlling Incontinence
Preventing Heart Disease the Easy Way
Lifestyle Changes for Heart Disease Prevention and Treatment
More...

Related Animations
 border=
Angioplasty
Coronary Bypass Surgery
What is a Heart Attack?
What is Cholesterol?
More...

Related Drug Information
 border=
Accupril
Altace
Avapro
Cartia XT
More...

Related News Articles
 border=
2 Techniques Found Effective in Carotid Artery Narrowing
For Even Healthy Men, Alcohol Seems to Lower Heart Attack Risk
Artery Plaque Rupture Can Occur Without Symptoms
Hydrating Kidney Patients With Sodium Bicarb Has Little Effect
More...

TUESDAY, May 13 (HealthDay News) -- A major trial has dashed the hope that the clot-preventing drug Plavix could help in the delicate balancing act needed to establish a blood vessel suitable for dialysis for kidney patients.

Giving Plavix (clopidogrel) did reduce the risk that a blood clot would block the vessel created by combining a vein and an artery, a standard procedure for kidney dialysis. But adding the clot-preventing drug did not increase the number of fistulas, as they are called, that could be used for artificial kidney treatment over the long run, the study authors reported.

Text Continues Below



The study was done because "early thrombosis [blood clotting] is one of the major causes of fistula failure," said Dr. Laura M. Dember, an associate professor of medicine at Boston University, and lead author of the report.

"What we found was that despite the reduction in thrombosis that was clear enough, there was an equal proportion of fistula failure," Dember said. "What is ultimately important is the usability of the fistula for dialysis."

The researchers published their findings in the May 14 issue of the Journal of the American Medical Association.

About 470,000 Americans have kidney failure and are kept alive by dialysis, in which their blood is run through a machine that filters out impurities. The preferred technique for linking to the artificial kidney is to create a fistula, which has lower rates of thrombosis -- blockage -- and infection than alternatives such as synthetic artery-vein grafts. But many fistulas never mature enough to allow dialysis.

The multi-center trial included 877 people with total or partial kidney failure who underwent surgery to create a fistula. Half were given Plavix for six weeks after the surgery, while the other half were not.

Plavix did reduce the risk of blockage by 37 percent over the six-week period. Among the 866 people who were tested, 12.2 percent of those given Plavix had a blockage, compared to 19.5 percent of those not given the anti-clotting drug.

Page:  1 | 2 | Next >>

Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 5/13/2008

Related Links
 border=
From Healthscout's partner site on incontinence, IncontinenceNetwork.com
Learn about urinary incontinence types, treatments, and more.
Get information about stress incontinence.
What is different about urge incontinence?





New Features

New ADHD Site!

SOURCES: Laura M. Dember, M.D., associate professor of medicine, Boston University School of Medicine; May 14, 2008, Journal of the American Medical Association


We comply with the HONcode standard for trustworthy health
information:
verify here.
About The HealthScout Network Contact Us
Copyright © 2001-2008. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service